The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, …

Background The relationship between the presence of antibodies to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains …

Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …

The effectiveness of COVID-19 vaccination in preventing new severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear. Here, …

Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …

We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the
BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, …

Background The management of complex orthopedic infections usually includes a prolonged
course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. …

We conducted voluntary Covid-19 testing programmes for symptomatic and asymptomatic
staff at a UK teaching hospital using naso-/oro-pharyngeal PCR testing and immunoassays for …

Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete
description of specific immune biomarkers. We present here a comprehensive multi-omic …